Introduction — This topic includes links to society and government-sponsored guidelines from selected countries and regions around the world. We will update these links periodically; newer versions of some guidelines may be available on each society's website. Some societies may require users to log in to access their guidelines.

The recommendations in the following guidelines may vary from those that appear in UpToDate topic reviews. Readers who are looking for UpToDate topic reviews should use the UpToDate search box to find the relevant content.

Links to other COVID-19 related guidelines are provided separately. (See "Society guideline links: COVID-19 – Index of guideline topics".)

International

●World Health Organization (WHO): Drugs to prevent COVID-19 – Living guideline (2021)

United States

●National Institutes of Health (NIH): COVID-19 treatment guidelines – Statement on tixagevimab plus cilgavimab (evusheld) for pre-exposure prophylaxis for SARS-CoV-2 infection (2022)

●NIH: COVID-19 treatment guidelines – Prevention of SARS-CoV-2 infection (2021)

●NIH: COVID-19 treatment guidelines – Statement on the emergency use authorization of bamlanivimab plus etesevimab as post-exposure prophylaxis for SARS-CoV-2 infection (2021)

●NIH: COVID-19 treatment guidelines – Statement on the emergency use authorization of casirivimab plus imdevimab as post-exposure prophylaxis for SARS-CoV-2 infection (2021)

●NIH: COVID-19 treatment guidelines – Statement on the prioritization of anti-SARS-CoV-2 monoclonal antibodies for the treatment or prevention of SARS-COV-2 infection when there are logistical constraints (2021)